Ivabradine Viatris

Ivabradine, the active ingredient in Ivabradine Viatris, is a If channel inhibitor presented as an oral tablet for oral use. It lowers heart rate and is indicated for chronic stable angina and heart failure with reduced ejection fraction in adult patients. GNH USA supplies Ivabradine Viatris as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ivabradine acts on the cardiac If current to reduce heart rate, benefiting conditions where heart rate control is essential.

Chronic stable angina: decreases the frequency of angina episodes by lowering myocardial oxygen demand. Heart failure with reduced ejection fraction: improves symptoms and outcomes by reducing heart rate without affecting contractility.

Ivabradine may cause a range of adverse reactions, most of which are dose‑related and reversible.

Common Side Effects: - Bradycardia: resting heart rate falls below the intended range. - Visual disturbances (phosphenes): transient luminous phenomena. - Headache: mild to moderate intensity. - Dizziness or light‑headedness. - Fatigue or general weakness. - Blurred vision.

Serious or Rare Side Effects: - Symptomatic bradycardia requiring medical intervention. - Atrial fibrillation or other arrhythmias. - Severe hypotension. - High‑grade atrioventricular block. - Persistent visual impairment. - Allergic reactions such as rash or angioedema.

Before initiating therapy, clinicians should evaluate patient‑specific factors and monitor for potential complications. - Monitor heart rate: ensure resting HR remains above 50 bpm. - Avoid in severe hepatic impairment: reduced clearance may increase exposure. - Use cautiously in sick‑sinus syndrome or AV‑node disease. - Do not combine with strong CYP3A4 inhibitors without dose adjustment. - Pregnancy and lactation: safety not established; prescribe only if benefits outweigh risks. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Ivabradine interacts with several drug classes, requiring careful assessment of concomitant therapy.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may markedly increase plasma concentrations. - Co‑administration with other heart‑rate‑lowering agents (beta‑blockers, digoxin): risk of excessive bradycardia. - Other If‑channel inhibitors: additive effect on heart rate.

Moderate Interactions (Monitor Closely):\n- Moderate CYP3A4 inhibitors (e.g., diltiazem, verapamil): may elevate levels modestly. - Drugs affecting AV‑node conduction (e.g., calcium‑channel blockers): monitor ECG for bradyarrhythmias. - Antihypertensives: potential for enhanced blood‑pressure reduction.